Neogenomics Inc. (NASDAQ: NEO) has sustained its Buy rating and a $19.00 price target from Needham with the firm's analysts highlighting the company's second-quarter 2024 financial performance, which surpassed consensus expectations for revenue and EBITDA.
The company experienced a deceleration in revenue growth, posting a 12% year-over-year increase in the second quarter, down from 14% in the previous quarter. The slowdown was attributed to a more moderate growth in Clinical Services, which saw a 15% year-over-year increase compared to 17% in the prior quarter. Advanced Diagnostics saw a 3% decline, consistent with the previous quarter's performance.
Neogenomics also reported a consistent rise in revenue per test, which went up by approximately 8.7% compared to the same period last year, marking the thirteenth consecutive quarter of improvement.
The growth has been partly driven by the company's pricing strategies and the volume of next-generation sequencing (NGS) tests, particularly its Neo Comprehensive and other NGS tests.
The firm also noted significant improvements in Neogenomics' profitability. The adjusted gross margin increased by 320 basis points year-over-year, reflecting enhancements in pricing, volume, and cost management. Moreover, the adjusted EBITDA margin saw a substantial rise of 800 basis points year-over-year.
NeoGenomics (NASDAQ:NEO) reported a robust 12% growth in revenue for the second quarter of 2024, reaching a total of $165 million. The financial growth is largely attributed to the company's Next-Generation Sequencing (NGS) business, which saw a notable 40% increase and now accounts for 30% of the total clinical revenue. Along with these strong results, NeoGenomics has also raised its revenue and adjusted EBITDA guidance for the year.
The company's NGS business continues to expand with plans to launch several new tests, including a rapid AML test and a liquid biopsy CTP test. Despite facing challenges in securing payments for large panel tests, NeoGenomics aims to grow its core business, accelerate advanced diagnostics, and drive value creation.
InvestingPro Insights
Neogenomics Inc. (NASDAQ:NEO) has shown some intriguing financial dynamics according to recent InvestingPro data. With a market capitalization of $1.87 billion and a notable revenue growth of 15.27% over the last twelve months as of Q1 2024, the company is demonstrating its ability to expand its financial base. This is consistent with the investment firm's recognition of the company’s revenue and EBITDA outperformance.
InvestingPro Tips indicate that analysts are optimistic about NEO's future, with four analysts revising their earnings upwards for the upcoming period and predicting profitability for the year. This aligns with the Buy rating and suggests that the company’s strategic initiatives may be starting to bear fruit. Moreover, the company's liquid assets exceed its short-term obligations, providing financial stability that could support ongoing operations and investment into growth areas.
For readers interested in a deeper dive into Neogenomics Inc.'s financial health and future prospects, more InvestingPro Tips are available, offering insights that could guide investment decisions. Use the coupon code PRONEWS24 to get up to 10% off a yearly Pro and a yearly or biyearly Pro+ subscription, and gain access to the full suite of tips and data that InvestingPro has to offer.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.